How Generative AI Is Redefining Biopharma R&D and Commercial Strategy

Photo by Bastian Riccardi on pexels Biopharma Industry is Building Resilience Through Innovation and IP Over the past five decades, biopharma has enjoyed a remarkable run, delivering robust growth (~7% CAGR) and nstrating a unique resilience. By developing defensible intellectual property in pursuit of innovative therapies, the industry has withstood economic downturns and sustained margins that few other sectors can match. This resilience is a core feature of the business model, established long before the modern digital transformation wave.